Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension

Mudit Mishra1, Ilayaraja Muthuramu1, Herman Kempen2 & Bart De Geest1✉

Therapeutic interventions with proven efficacy in heart failure with reduced ejection fraction (HFrEF) have been unsuccessful in heart failure with preserved ejection fraction (HFpEF). The modifiable risk factor with the greatest impact on the development of HFpEF is hypertension. The objectives of this study were to establish a murine model of HFpEF associated with hypertension and to evaluate the effect of apo A-I\textsuperscript{Milano} nanoparticles (MDCO-216) on established HFpEF in this model. Subcutaneous infusion of angiotensin II in combination with 1% NaCl in the drinking water was started at the age of 12 weeks in male C57BL/6N mice and continued for the entire duration of the experiment. Treatment with MDCO-216 partially reversed established cardiac hypertrophy, cardiomyocyte hypertrophy, capillary rarefaction, and perivascular fibrosis in this model. Pressure-volume loop analysis was consistent with HFpEF in hypertension mice as evidenced by the preserved ejection fraction and a significant reduction of cardiac output (7.78 ± 0.56 ml/min versus 10.5 ± 0.7 ml/min; p < 0.01) and of the peak filling rate (p < 0.05). MDCO-216 completely reversed cardiac dysfunction and abolished heart failure as evidenced by the normal lung weight and normal biomarkers of heart failure. In conclusion, apo A-I\textsuperscript{Milano} nanoparticles constitute an effective treatment for established hypertension-associated HFpEF.

Heart failure is the inability of the heart to pump blood forward at a sufficient cardiac output to meet the metabolic requirements of organs and tissues (termed forward failure) or the ability to do this only at the expense of pathologically elevated cardiac filling pressures (termed backward failure) or a combination of both. The distribution of ejection fraction in patients admitted for acutely decompensated heart failure is bimodal\textsuperscript{1,2}. A distinction is made between heart failure with reduced ejection fraction (ejection fraction < 40%) and heart failure with preserved ejection fraction (HFpEF) (ejection fraction ≥ 50%). This distinction reflects different pathophysiological mechanisms\textsuperscript{3,4} that ultimately are responsible for left ventricular chamber dilatation in HFrEF and a normal or quasi-normal left ventricular chamber size in HFpEF\textsuperscript{5}. Ventricular remodelling induced by age, hypertension, and in some cases diabetes mellitus may generate a slowly progressive substrate upon which HFpEF develops whereas accelerated and larger-scale myocyte loss and/or dysfunction is required for development of HFrEF\textsuperscript{3}. Ventricular morphology in HFpEF is characterised by an increased ratio of ventricular mass to chamber volume in comparison to healthy controls\textsuperscript{6,7}. This type of left ventricular remodelling can also be detected in a significant proportion of individuals with pressure overload induced by arterial hypertension. HFpEF can develop as a progression of asymptomatic hypertensive heart disease\textsuperscript{8,9}. Hypertension is the single largest risk factor for the development of heart failure\textsuperscript{10} but is rarely a solitary cause for HFrEF\textsuperscript{11}. In contrast, the modifiable risk factor with the greatest impact on the development of HFpEF is hypertension\textsuperscript{12}. Diastolic dysfunction is an important risk factor for the development of HFpEF.\textsuperscript{13,14,15,16,17}
Apolipoprotein (apo) A-I is the main apolipoprotein of HDL. The objectives of the current study were twofold. The first objective was to generate a new murine model of hypertension-associated HFpEF without the need to perform a unilateral nephrectomy. The second objective was to evaluate the therapeutic efficacy of apo A-I Milano nanoparticles in hypertension-associated HFpEF. MDCO-216 is a pharmaceutical product with proven clinical safety26–29 that comprises highly purified dimeric apoA-I Milano produced by recombinant DNA technology and complexed with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine. We specifically evaluated whether administration of apo A-I Milano nanoparticles can reverse established hypertension in C57BL/6 N mice induced by angiotensin II and were given tap water to drink. Endpoint analyses were performed at the age of 16 weeks and for 4 weeks and nine days in buffer hypertension mice and MDCO-216 hypertension mice (Fig. 1). No significant differences of lipoprotein cholesterol levels, plasma insulin, or blood glucose were observed between the four groups at the time of sacrifice (Table 1). The rise in ventricular pressure in healthy subjects, impaired active myocardial relaxation and ventricular stiffness in subjects with HFpEF increase ventricular filling pressures, which are upstream transmitted to the left atrium and to the pulmonary circulation and result in signs and symptoms of heart failure.

Most randomized clinical trials in subjects with heart failure have been restricted to HFrEF patients since ejection fraction was a major inclusion criterion in these studies. Inhibition of the renin-angiotensin-aldosterone system and β-receptor blockade enhance survival and decrease the frequency of hospitalizations in patients with HFrEF18. In contrast to the progress in the treatment of HFrEF, no therapy has been found to have clinical benefit in individuals with HFpEF and no intervention has resulted in decreased mortality in patients with HFpEF19,20.

Previous studies from our lab provide powerful evidence that high-density lipoproteins (HDL) exert direct effects on the myocardium that are entirely independent of any effect on the epicardial coronary arteries21–25. Apolipoprotein (apo) A-I is the main apolipoprotein of HDL. The objectives of the current study were twofold. The first objective was to generate a new murine model of hypertension-associated HFpEF without the need to perform a unilateral nephrectomy. The second objective was to evaluate the therapeutic efficacy of apo A-I Milano nanoparticles in hypertension-associated HFpEF. MDCO-216 is a pharmaceutical product with proven clinical safety26–29 that comprises highly purified dimeric apoA-I Milano produced by recombinant DNA technology and complexed with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine. We specifically evaluated whether administration of apo A-I Milano nanoparticles can reverse established HFpEF in C57BL/6 N mice induced by angiotensin II infusion combined with 1% NaCl in the drinking water.

### Table 1. Total, non-HDL, and HDL cholesterol plasma levels, insulin plasma levels, and blood glucose levels in C57BL/6 N mice at time of sacrifice. All data are expressed as means ± SEM (n = 15).

|                      | Reference control | Reference hypertension | Buffer hypertension | MDCO-216 hypertension |
|----------------------|-------------------|------------------------|---------------------|-----------------------|
| Total cholesterol (mmol/L) | 1.76 ± 0.08 | 1.72 ± 0.11 | 1.78 ± 0.09 | 1.67 ± 0.12 |
| Non-HDL cholesterol (mmol/L) | 0.533 ± 0.040 | 0.474 ± 0.076 | 0.526 ± 0.062 | 0.511 ± 0.065 |
| HDL cholesterol (mmol/L) | 1.22 ± 0.09 | 1.24 ± 0.07 | 1.26 ± 0.10 | 1.16 ± 0.10 |
| Insulin (pmol/L) | 113 ± 9 | 129 ± 16 | 144 ± 13 | 128 ± 15 |
| Glucose (mmol/L) | 6.21 ± 0.24 | 5.37 ± 0.38 | 5.93 ± 0.28 | 5.89 ± 0.17 |

HFpEF hallmark of HFpEF and includes impairment in active myocardial relaxation and reduced distensibility of the myocardium13,14. Hypertension is strongly associated with left ventricular diastolic dysfunction15–17. Whereas low ventricular pressures and vigorous myocardial elastic recoil potentiate ventricular filling without a significant rise in ventricular pressure in healthy subjects, impaired active myocardial relaxation and ventricular stiffness in subjects with HFpEF increase ventricular filling pressures, which are upstream transmitted to the left atrium and to the pulmonary circulation and result in signs and symptoms of heart failure.

Figure 1. Schematic representation of the study design.

### Results

#### Study design to evaluate the effect of apo A-I Milano nanoparticles on established HFpEF

The study design is illustrated in Fig. 1. Subcutaneous infusion of angiotensin II (600 ng/kg/min) in combination with 1% NaCl in the drinking water was initiated at the age of 12 weeks in male C57BL/6 N mice and continued for 4 weeks in reference hypertension mice and for 4 weeks and nine days in buffer hypertension mice and MDCO-216 hypertension mice. Mice of the reference control group received an osmotic pump containing no angiotensin II and were given tap water to drink. Endpoint analyses were performed at the age of 16 weeks in reference control and in reference hypertension mice. MDCO-216 hypertension mice were treated with 5 intraperitoneal administrations of 100 mg/kg (protein concentration) of apo A-I Milano nanoparticles (MDCO-216) at an interval of 48 hours each starting at the age of 16 weeks. Buffer hypertension mice were injected with the same volume of control buffer. Endpoints were determined at the age of 16 weeks and 9 days in buffer hypertension mice and in MDCO-216 hypertension mice (Fig. 1). No significant differences of lipoprotein cholesterol levels, plasma insulin, or blood glucose were observed between the four groups at the time of sacrifice (Table 1).

#### Treatment with apo A-I Milano nanoparticles partially reverses established cardiac hypertrophy in C57BL/6 N mice with angiotensin II/1% NaCl-induced hypertension

Infusion of angiotensin II in combination with 1% NaCl in the drinking water resulted in a 1.41-fold (p < 0.001) increase of heart weight in reference hypertension mice compared to reference control mice (Fig. 2A). Heart weight in MDCO-216 hypertension mice was 11.1% (p < 0.05) and 16.0% (p < 0.05) lower than in reference hypertension mice and buffer hypertension mice, respectively (Fig. 2B). Similar differences were observed when heart weight was normalised.
to tibia length (Fig. 2B). Left ventricular weight was 1.44-fold (p < 0.001) higher and 1.56-fold (p < 0.001) higher in reference hypertension mice and in buffer hypertension mice, respectively, than in reference control mice (Fig. 2C). Left ventricular weight was 14.1% (p < 0.05) lower in MDCO-216 hypertension mice than in buffer hypertension mice. Similar differences were present when left ventricular weight was normalised to tibia length (Fig. 2D). Tibia length (data not shown) and body weight (Fig. 2E) were similar in all groups. Quantification of left ventricular wall area (LV wall area) based on morphometric analysis of Sirius-red stained cross-sections independently confirmed the degree of left ventricular hypertrophy in mice with angiotensin II/1% NaCl-induced hypertension (Fig. 2F). Representative Sirius red-stained cross-sections of hearts of reference control, reference hypertension, buffer hypertension, and MDCO-216 hypertension mice illustrating the degree of left ventricular hypertrophy are shown in Fig. 2G. Taken together, treatment with MDCO-216 partially reverses cardiac hypertrophy under conditions of continued subcutaneous infusion of angiotensin II (600 ng/kg/min) in combination with 1% NaCl in the drinking water.

**MDCO-216 reverses heart failure in C57BL/6 N mice with angiotensin II/1% NaCl-induced hypertension.** Figure 3A illustrates plasma levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP), a biomarker of heart failure. NT-proBNP levels were increased by 1.33-fold (p < 0.001) and by 1.22-fold (p < 0.01) in reference hypertension mice and in buffer hypertension mice, respectively, compared to reference control mice. NT-pro BNP levels in MDCO-216 hypertension mice were reduced by 19.0% (p < 0.01) and by 11.7% (p < 0.01) compared to reference hypertension mice and buffer hypertension mice, respectively.
Moreover, NT-proBNP levels in MDCO-216 hypertension mice were unaltered compared to reference control mice. A 1.21-fold ($p < 0.01$) increase of wet lung weight was observed in buffer hypertension mice compared to reference control mice (Fig. 3B). Wet lung weight was 16.4% ($p < 0.01$) lower in MDCO-216 hypertension mice than in buffer hypertension mice and entirely similar compared to reference control mice. Taken together, MDCO-216 reverses heart failure in C57BL/6 N mice with angiotensin II/1% NaCl-induced hypertension.

**Treatment with apo A-I-Milano nanoparticles reverses cardiomyocyte hypertrophy, capillary rarefaction, and perivascular fibrosis in C57BL/6 N mice with angiotensin II/1% NaCl-induced hypertension.** Microscopic analysis demonstrated that cardiomyocyte cross-sectional area was increased by 1.49-fold ($p < 0.001$) and by 1.60-fold ($p < 0.001$) in reference hypertension mice and in buffer hypertension mice, respectively, compared to reference control mice. Cardiomyocyte cross-sectional area in MDCO-216 hypertension mice was reduced by 26.3% ($p < 0.01$) and by 31.4% ($p < 0.01$) compared to reference hypertension mice and buffer hypertension mice, respectively (Fig. 4A). Myocardial capillary density was reduced by 33.8% ($p < 0.001$) and by 28.5% ($p < 0.001$) in reference hypertension mice and in buffer hypertension mice, respectively, compared to reference control mice (Fig. 4B). Myocardial capillary density in MDCO-216 hypertension mice was 1.38-fold ($p < 0.05$) and 1.28-fold ($p < 0.05$) higher than in reference hypertension mice and in buffer hypertension mice, respectively (Fig. 4B). Interstitial fibrosis in the myocardium was markedly increased in the three hypertension groups ($p < 0.001$) compared to reference control mice. A 17.7% ($p < 0.05$) reduction of interstitial fibrosis was observed in MDCO-216 hypertension mice compared to buffer hypertension mice (Fig. 4C). Perivascular fibrosis was significantly ($p < 0.001$) increased in the three groups with angiotensin II/1% NaCl-induced hypertension (Fig. 4D). Perivascular fibrosis in MDCO-216 hypertension mice was reduced by 29.0% ($p < 0.05$) and by 33.1% ($p < 0.01$) compared to reference hypertension mice and buffer hypertension mice, respectively (Fig. 4D). Representative photomicrographs showing laminin-stained cardiomyocytes, CD31-positive capillaries, and Sirius-red-stained collagen are contained in Fig. 5. Taken together, MDCO-216 reverses cardiomyocyte hypertrophy, capillary rarefaction, and perivascular fibrosis in C57BL/6 N mice with angiotensin II/1% NaCl-induced hypertension.

**MDCO-216 restores cardiac function in mice with angiotensin II/1% NaCl-induced hypertension.** Hemodynamic data in reference control mice and in the three hypertension groups were obtained using the Millar Pressure-Volume Loop System (MPVS) and are summarized in Table 2. The hypertension model was characterised by a significantly increased maximum systolic pressure ($P_{\text{max}}$) and a significant elevation of the end-systolic pressure ($P_s$). Ejection fraction was preserved in reference hypertension mice and in buffer hypertension mice compared to control reference mice since no left ventricular dilatation occurred. As a matter of fact, the end-diastolic volume (EDV) was reduced by 14.5% ($p < 0.05$) and by 15.9% ($p < 0.01$) in reference hypertension mice and buffer hypertension mice, respectively (Fig. 2A). End-diastolic volume in MDCO-216 hypertension mice was partially normalised ($p < 0.05$). The end-systolic elastance ($E_s$), which is the slope of the end-systolic pressure-volume relationship (ESPVR) and is a load-independent parameter of left ventricular contractility, was reduced by 35.4% ($p < 0.01$) and 38.4% ($p < 0.001$) in reference hypertension mice and in buffer hypertension mice, respectively, compared to reference control mice. In contrast, $E_s$ in MDCO-216 hypertension mice was 1.63-fold ($p < 0.001$) higher than in reference hypertension mice and was similar compared to reference control mice. The peak emptying rate ($dV/dt_{\text{min}}$) was not significantly different in reference hypertension mice and in buffer hypertension mice compared to reference control mice. However, the absolute value of the peak emptying rate was significantly higher in MDCO-216 hypertension mice compared to both reference hypertension mice and buffer hypertension mice. The absolute value of the peak emptying rate was significantly higher in MDCO-216 hypertension mice compared to both reference hypertension mice and buffer hypertension mice.
and buffer hypertension mice. Taken together, global systolic function was moderately affected in mice with angiotensin II/1% NaCl-induced hypertension and was normalised by treatment with apo A-I \textsubscript{Ldlα} nanoparticles.

Diastolic dysfunction in reference hypertension mice was evident by the significantly (p < 0.05) increased end-diastolic pressure (EDP), the 1.18-fold (p < 0.05) increase of the time constant of isovolumetric relaxation tau, and the 25.8% (p < 0.05) decrease of the peak emptying rate (dV/dt \textsubscript{max}) compared to control reference mice (Table 2). Diastolic function in MDCO-216 hypertension mice was characterised by a normalisation of the end-diastolic pressure, the time constant of isovolumetric relaxation, and dV/dt \textsubscript{max}. Compared to reference hypertension mice, the time constant of isovolumetric relaxation tau in MDCO-216 hypertension mice was decreased by 12.5% (p < 0.05) and dV/dt \textsubscript{max} was increased by 1.45-fold (p < 0.001). Cardiac dysfunction in reference hypertension mice and in buffer hypertension mice induced a significant (p < 0.01) decrease of stroke volume compared to reference control mice whereas stroke volume was normalised in MDCO-216 hypertension mice. Cardiac output was decreased by 26.2% (p < 0.01) and by 26.5% (p < 0.01) in reference hypertension mice and in buffer hypertension mice, respectively, compared to reference control mice. A 1.38-fold (p < 0.01) and a 1.39-fold increase of cardiac output was observed in MDCO-216 hypertension mice compared to reference hypertension mice and buffer hypertension mice, respectively (Table 2). The effective arterial elastance (E\textsubscript{a}), which correspond to the end-systolic pressure (P\textsubscript{es})/stroke volume (SV) ratio and is an index of arterial vascular load, was 1.49-fold (p < 0.01) and 1.96-fold (p < 0.001) higher in reference hypertension mice and in buffer hypertension mice, respectively, compared to reference control mice. MDCO-216 hypertension mice were characterised by a 21.8% (p < 0.05) and a 40.8% (p < 0.01) decrease of E\textsubscript{a} compared to reference hypertension mice and buffer hypertension mice, respectively. The E\textsubscript{a}/E\textsubscript{es} ratio was significantly (p < 0.001) increased in reference hypertension mice and in buffer hypertension mice compared to reference control mice, indicating impaired ventriculo-arterial coupling. Ventriculo-arterial coupling was completely restored in MDCO-216 hypertension

**Figure 4.** MDCO-216 reverses cardiomyocyte hypertrophy, capillary rarefaction, and perivascular fibrosis in C57BL/6N mice with angiotensin II/1% NaCl-induced hypertension. All data are expressed as means ± SEM (n = 12).
mice (Table 2). A summary of hemodynamic data is provided in Supplementary Fig. S1. Taken together, MDCO-216 restores cardiac function in mice with angiotensin II/1% NaCl-induced HFpEF.

**Treatment with apo A-I_\text{Milano} nanoparticles reduces oxidative stress in mice with angiotensin II/1% NaCl-induced HFpEF.** Plasma thiobarbituric acid reactive substances (TBARS) levels were quantified to evaluate oxidative stress (Fig. 6A). Plasma TBARS were increased by 1.91-fold ($p < 0.01$) and by 1.46-fold ($p < 0.01$) in reference hypertension mice and in buffer hypertension mice, respectively, compared to reference control mice (Fig. 6A). In MDCO-216 hypertension mice, plasma TBARS were reduced by 46.0% ($p < 0.05$) and by 29.3% ($p < 0.05$) compared to reference hypertension mice and buffer hypertension mice, respectively. Superoxide dismutases (SODs) constitute a major antioxidant defense against oxidative stress. SOD activity was 45.1% ($p < 0.001$) and 40.2% ($p < 0.001$) lower in reference hypertension and buffer hypertension mice, respectively, than in reference control mice (Fig. 6B). SOD activity was fully restored in MDCO-216 hypertension mice and was increased by 1.68-fold ($p < 0.001$) and by 1.54-fold ($p < 0.001$) compared to reference hypertension mice and buffer hypertension mice, respectively.

**Discussion**

The principal findings of the current study are that (1) infusion of angiotensin II at a dose of 600 ng/kg/min combined with 1% NaCl in the drinking water constitutes a model of hypertension-associated HFpEF characterized by cardiac hypertrophy, capillary rarefaction, prominent interstitial fibrosis and perivascular fibrosis, oxidative stress, pronounced cardiac dysfunction, and pulmonary congestion; (2) treatment with apo A-I_\text{Milano} nanoparticles reverses oxidative stress, capillary rarefaction, perivascular fibrosis, cardiac dysfunction, and heart failure.

The renin-angiotensin-aldosterone system is the key homeostatic hormonal mechanism that regulates arterial pressure in order to ensure sufficient tissue perfusion. However, this system also results in pro-inflammatory and profibrotic effects. Aldosterone may mediate cardiac fibrosis in the setting of arterial hypertension. Previous murine studies have shown that the combination of unilateral nephrectomy, aldosterone infusion for a duration of four weeks, and 1% NaCl in the drinking water leads to the development of hypertension-associated HFpEF characterised by eccentric left ventricular hypertrophy, diastolic dysfunction, and pulmonary congestion. The requirement for a unilateral nephrectomy is a significant disadvantage of this model.

**Figure 5.** Immunohistochemical and histochemical analysis of reference control, reference hypertension, buffer hypertension, and MDCO-216 hypertension mice. Representative photomicrographs show laminin-stained cardiomyocytes, CD31-positive capillaries, and Sirius-red-stained collagen. Scale bar represents 50 μm.
Table 2. Overview of hemodynamic data in reference control mice, reference hypertension mice, buffer hypertension, and MDCO-216 hypertension mice. $P_{\text{max}}$: maximum systolic pressure. $P_e$: end-systolic pressure. $dP/dt_{\text{max}}$: peak rate of isovolumetric contraction. PRSW: preload recruitable stroke work. $E_{\text{es}}$: end-systolic elastance. $P_{\text{di}}$: end-diastolic pressure. $dP/dt_{\text{min}}$: peak rate of isovolumetric relaxation. Tau: time constant of isovolumetric relaxation. EDPVR: end diastolic pressure-volume relationship. Ea: arterial elastance. Ea/Ees: ventriculo-arterial coupling ratio. Angiotensin II (600 ng/kg/min) was infused via an Alzet osmotic pump and the drinking water contained 1 NaCl for 4 weeks in the reference hypertension mice. This was continued for an additional 9 days in the buffer hypertension and MDCO-216 hypertension groups. Five intraperitoneal injections of recombinant HDLMilano (MDCO-216) (100 mg/kg) or an equivalent volume of control buffer were executed with a 48-hour interval starting from 4 weeks after the initiation of angiotensin II/NaCl. All data are expressed as means $\pm$ SEM. $^*$p < 0.05; $^{**}$p < 0.01; $^{***}$p < 0.001 versus reference control. $^*$p < 0.05; $^{**}$p < 0.01; $^{***}$p < 0.001 versus reference hypertension.$^*$p < 0.05; $^{**}$p < 0.01; $^{***}$p < 0.001 versus control buffer hypertension.

![Figure 6](https://www.nature.com/scientificreports/)

**Figure 6.** MDCO-216 reduces oxidative stress in with angiotensin II/1% NaCl-induced hypertension. Data represent means $\pm$ SEM (n = 10).
BNP are induced by myocardial stretch46. N-terminal prohormone of brain natriuretic peptide (NT-proBNP) is biomarkers in subjects with HFrEF and in clinical patients with HFpEF. Transcription and release of ANP and brain natriuretic peptide (BNP), also known as B-type natriuretic peptide (BNP), are the most widely employed wet lung weight or of increased biomarkers of heart failure. The natriuretic peptides, atrial natriuretic peptide and hypertrophy, capillary rarefaction, increased interstitial and perivascular fibrosis, oxidative stress, pronounced cardiac dysfunction, and pulmonary congestion. Diagnosis of heart failure was based on the presence of increased wet lung weight or of increased biomarkers of heart failure. The natriuretic peptides, atrial natriuretic peptide and brain natriuretic peptide (BNP), also known as B-type natriuretic peptide (BNP), are the most widely employed biomarkers in subjects with HFrEF and in clinical patients with HFrEF. Transcription and release of ANP and BNP are induced by myocardial stretch46. N-terminal prohormone of brain natriuretic peptide (NT-proBNP) is the biologically inactive fragment that is formed following cleavage of proBNP into the active hormone BNP47. Whereas NT-proBNP levels were increased in reference hypertension mice and buffer hypertension mice, levels were completely normalised in MDCO-216 hypertension mice.

Cardiomyocyte hypertrophy and myocardial fibrosis are hallmarks of hypertensive heart disease. Elevated shear stress combined with low-grade systemic inflammation promote endothelial damage in hypertension58. Endothelial damage and inflammation promote perivascular fibrosis characterised by the accumulation of collagen in the adventitia of intramural arteries. Hypertension also induces structural and functional alterations in the microcirculation paralleled by the development of microvascular remodelling and rarefaction48. At the microscopic level, prominent observations in hypertension mice treated with MDCO-216 were regression of cardiomyocytes hypertrophy, restored capillary density, and significantly reduced perivascular fibrosis compared to reference hypertension mice. HDL are multimolecular platforms and these multimolecular platforms exert pleiotropic effects including anti-inflammatory and anti-oxidative properties, immunomodulatory effects, endothelial-protective properties, and augmented endothelial progenitor cell number and function49,50. Moreover, HDL downregulates angiotensin II type 1 receptor51,52. HDL also has an anti-fibrotic effects. HDL decreases transforming growth factor-β1-induced collagen accumulation53 and reduces transforming growth factor-β1 in the myocardium54. Furthermore, HDL has been demonstrated to decrease endothelial-mesenchymal transition in aortic endothelial cells in vitro induced by transforming growth factor-β154.

The restoration of cardiac function following MDCO-216 treatment was prominent. The increase of capillary density and the regression of perivascular fibrosis may improve myocardial function via an improvement of the myocardial microcirculation. In addition, direct electrophysiological effects elicited by HDL can be postulated. Reconstituted HDL containing wild-type apo A-I shortened repolarization in cardiomyocytes isolated from rabbits55. Moreover, infusion of reconstituted HDL has been demonstrated to shorten the heart-rate corrected QT interval on surface electrocardiograms in humans56. Microdomain-specific localization of ion channels affects their function57 and HDL regulates the distribution of cholesterol between raft and non-raft membrane fractions58.

Reactive oxygen species and oxidative stress are important contributors to the pathogenesis of heart failure influencing many key aspects of the failing heart phenotype such as myocardial hypertrophy, extracellular matrix remodelling, contractile dysfunction, and arrhythmias59. Exposure of cardiac fibroblasts to superoxide anion increases the production of the potent fibrogenic cytokine transforming growth factor-β160.

The restoration of cardiac function following MDCO-216 treatment was prominent. The increase of capillary density and the regression of perivascular fibrosis may improve myocardial function via an improvement of the myocardial microcirculation. In addition, direct electrophysiological effects elicited by HDL can be postulated. Reconstituted HDL containing wild-type apo A-I shortened repolarization in cardiomyocytes isolated from rabbits55. Moreover, infusion of reconstituted HDL has been demonstrated to shorten the heart-rate corrected QT interval on surface electrocardiograms in humans56. Microdomain-specific localization of ion channels affects their function57 and HDL regulates the distribution of cholesterol between raft and non-raft membrane fractions58.

Apo A-I Milano nanoparticles. MDCO-216 is a 1:1 by weight complex of dimeric apo A-I Milano produced by recombinant DNA technology and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine62 and was supplied by The Medicines Company (Parsippany, NJ, USA) as a solution in buffer containing mannitol 43.6 mM, sucrose 181 mM, NaH2PO4·2H2O 3.46 mM, and 8.43 mM Na2HPO4·7H2O. Non-denaturing polyacrylamide gradient-gel electrophoresis has previously demonstrated that these nanoparticles are characterised by an apparent diameter of 8 nm and that no free apo A-I Milano was observed63.

Materials and Methods

Apo A-I Milano nanoparticles. MDCO-216 is a 1:1 by weight complex of dimeric apo A-I Milano produced by recombinant DNA technology and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine62 and was supplied by The Medicines Company (Parsippany, NJ, USA) as a solution in buffer containing mannitol 43.6 mM, sucrose 181 mM, NaH2PO4·2H2O 3.46 mM, and 8.43 mM Na2HPO4·7H2O. Non-denaturing polyacrylamide gradient-gel electrophoresis has previously demonstrated that these nanoparticles are characterised by an apparent diameter of 8 nm and that no free apo A-I Milano was observed63.

In vivo experiments and study design. All investigations were performed in accordance with the European legislation on protection of animals used for scientific purposes (Directive 2010/63/EU) and all experimental procedures in animals were executed in accordance with protocols approved by the Institutional Animal Care and Research Advisory Committee of the Catholic University of Leuven (Approval number: P191/2015). C57BL/6N mice, originally obtained from Taconic (Ry, Denmark), were locally bred at the semi-specific pathogen free facility of the KU Leuven at Gasthuisberg. All experimental mice included in the study were male and were maintained on standard chow diet (Sniff Spezialdiäten GMBH, Soest, Germany).
The study design is illustrated in Fig. 1. Subcutaneous infusion of angiotensin II (600 ng/kg/min) using an ALZET osmotic pump (models 2004 and models 2006) (DURECT Corporation ALZET Osmotic Pumps, Cupertino, CA) in combination with 1% NaCl in the drinking water was started at the age of 12 weeks and continued for 4 weeks in reference hypertension mice and for 4 weeks and nine days in buffer hypertension mice. Mice of the reference control group received an osmotic pump containing no angiotensin II and were given tap water to drink. Endpoint analyses in reference control and in reference hypertension mice were performed at the age of 16 weeks. MDCO-216 hypertension mice were treated with 5 intraperitoneal administrations of 100 mg/kg (protein concentration) of MDCO-216 at an interval of 48 hours each starting at the age of 16 weeks. Buffer hypertension mice were injected with the same volume of control buffer. Endpoints in buffer hypertension mice and in MDCO-216 hypertension mice were determined at the age of 16 weeks and 9 days, 24 hours after the last injection (Fig. 1). In the first experimental layer, mice were assigned for quantification of hemodynamic parameters and for histochemical and immunohistochemical determinations. Mice in the second experimental layer were not subjected to perfusion fixation and were used for determination of tissue and organ weights.

Group assignment at the start of the study was performed at random. No mice died during the investigation. All randomised animals were included in the analysis. Endpoint parameters were quantified by investigators who were blinded to the specific group allocation of the animals. Unblinding of animal numbers corresponding to the different allocation groups was performed following finalisation of measurements.

**In vivo hemodynamic pressure-volume loop measurements.** Invasive hemodynamic measurements were performed before sacrifice following anaesthesia induced by intraperitoneal administration of 1.2 g/kg urethane (Sigma). Measurements were performed using Millar’s Mikro-Tip ultra-miniature pressure-volume (PV) loop catheter PVR-1035 (1.0 French polyimide catheter), the MPVS Ultra Single Segment pressure-volume unit, and a PowerLab 16/35 data acquisition system (ADInstruments Ltd, Oxford, United Kingdom) as described before24.

**Blood sampling.** Blood was obtained by sampling of the retro-orbital plexus. Blood coagulation was prevented with 0.1 volume of 136 mmol/L trisodium citrate. Subsequently, plasma was immediately separated by centrifugation at 1100 × g for 10 min and was stored at −20 °C.

**Analysis of lipid peroxidation and quantification of superoxide dismutase in plasma.** Measurement of Thiobarbituric Acid Reactive Substances (TBARS) used for quantification of lipid peroxidation was performed according to the instructions of the manufacturer (Cayman Chemical, Ann Arbor, MI, USA). Superoxide dismutase activity was quantified using the Superoxide Dismutase Assay kit (Cayman Chemical, Ann Arbor, MI, USA) as described previously62.

**Determination of plasma levels of insulin of mouse N-terminal prohormone of brain natriuretic peptide (NT-proBNP).** Murine insulin levels in plasma were quantified using the Ultra Sensitive Mouse Insulin enzyme-linked immunosorbent assay (ELISA) kit (Crystal Chem, Elk Grove Village, USA). Plasma NT-proBNP levels were quantified using Mouse NT-proBNP (N-terminal pro-Brain Natriuretic Peptide) ELISA (Elabscience, Wuhan, China).

**Histological analyses.** Histological parameters were quantified as described before63. After hemodynamic analyses, mice were perfused via the abdominal aorta with phosphate-buffered saline and hearts were arrested in diastole by KCl (100 μM; 0.1 mol/L), followed by perfusion fixation with 1% paraformaldehyde in phosphate-buffered saline. Thereafter, hearts were post-fixed overnight in 1% paraformaldehyde and embedded in paraffin. Cross-sections of 6 μm thickness at 130 μm spaced intervals were made extending from the apex to the basal part of the left ventricle. Comparative sections were analysed for all histological analyses by using the same slide numbers (1 to 40 from apex to base) and cross-section numbers (1–10).

LV wall area (including the septum) was quantified by morphometric analysis on mosaic images of Sirius red-stained heart cross-sections using AxioVision 4.6 software (Zeiss, Zaventem, Belgium). Al geometric measurements were computed in a blinded fashion from tissue sections of 4 separate regions and the average value was used to represent that animal for statistical purposes.

To measure collagen content in the interstitium, Sirius Red staining was performed as described by Junqueira et al.64. Sirius Red polarisation microscopy on a Leica BME microscope with KS300 software (Zeiss) was applied for image acquisition to quantify thick tightly packed mature collagen fibres as orange-red birefringent and loosely packed less cross-linked and immature collagen fibres as yellow-green birefringent. Collagen positive area was normalised to the LV wall area and was expressed as a percentage. Total collagen positive area (%) was automatically quantified as a sum of orange-red birefringent and yellow-green birefringent using AxioVision 4.6 software package (Zeiss, Zaventem, Belgium). Any perivascular fibrosis was excluded from this analysis. Perivascular fibrosis was quantified as the ratio of the fibrosis area surrounding the vessel to the total vessel area using AxioVision 4.6 software package (Zeiss). Two mid-ventricular sections were studied per animal65.

Cardiomyocyte hypertrophy was analysed on paraffin sections stained with rabbit anti-mouse laminin (Sigma; 1/50) by measuring the cardiomyocyte cross-sectional area (μm²) of at least 200 randomly selected cardiomyocytes in the LV myocardium. Capillary density in the myocardium was determined on CD31 stained sections using rat anti-mouse CD31 antibodies (BD; 1/500). Two mid-ventricular cross-sections were analysed per mouse65,66.
Statistical analyses. At the end of the study, data of all surviving mice were included in the analysis. Investigators who performed endpoint analyses were blinded to group allocation. Unblinding of animal numbers corresponding to specific allocation groups was performed at completion of measurements. Statistical analysis was performed as outlined before.\(^{21,22}\). Statistical expression as means ± standard error of the mean (SEM). Minimally required sample size calculation (\(n = 12\)) for proving the effect of MDCO-216 treatment on hemodynamic parameters in hypertension mice was based on a statistical power of 85%, a two-sided cut-off value of statistical significance of 0.05, a difference of main hemodynamic parameters at the population level of 20%, and a pooled standard deviation at population level of 16%. Parameters between the reference control, reference hypertensive, buffer hypertensive and MDCO-216 hypertensive groups were compared by one-way analysis of variance followed by Tukey's multiple comparisons test using GraphPad Instat (GraphPad Software, San Diego, CA, USA). When the assumption of sampling from populations with identical standard deviations was not met, a logarithmic transformation was performed. When the assumption of sampling from populations with Gaussian distributions was not met, a Kruskal–Wallis test was performed followed by Dunn's multiple comparisons post-test. A two-sided p-value of less than 0.05 was considered statistically significant.

Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 22 January 2020; Accepted: 2 May 2020; Published online: 20 May 2020

References
1. Fonarow, G. C. et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50, 768–777, https://doi.org/10.1016/j.jacc.2007.04.064 (2007).
2. Dunlay, S. M., Roger, V. L., Weston, S. A., Jiang, R. & Redfield, M. M. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 5, 720–726, https://doi.org/10.1161/CIRCHEARTFAILURE.111.966366 (2012).
3. Borlaug, B. A. & Redfield, M. M. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123, 2006–2013; discussion 2014, https://doi.org/10.1161/CIRCULATIONAHA.110.954388 (2011).
4. Paulus, W. J. & Tschoppe, C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62, 263–271, https://doi.org/10.1016/j.jacc.2013.02.092 (2013).
5. Little, W. C. & Zile, M. R. HFrEF: cardiovascular abnormalities not just comorbidities. Circ Heart Fail 5, 669–671, https://doi.org/10.1161/CIRCHEARTFAILURE.112.972265 (2012).
6. Lam, C. S. et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115, 1982–1990, https://doi.org/10.1161/CIRCULATIONAHA.106.659763 (2007).
7. Klahroh, M. et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 43, 1432–1438, https://doi.org/10.1016/j.jacc.2003.11.040 (2004).
8. Melenovsky, V. et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 49, 198–207, https://doi.org/10.1016/j.jacc.2006.08.050 (2007).
9. Borlaug, B. A., Lam, C. S., Roger, V. L., Rodeheffer, R. J. & Redfield, M. M. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 54, 410–418, https://doi.org/10.1016/j.jacc.2009.05.013 (2009).
10. Levy, D., Larson, M. G., Vasan, R. S., Kannel, W. B. & Ho, K. K. The progression from hypertension to congestive heart failure. Jama 275, 1557–1562, https://doi.org/10.1001/jama.1996.03530440037034 (1996).
11. Felker, G. M. et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342, 1077–1084, https://doi.org/10.1056/NEJMB200004133421302 (2000).
12. Nadruz, W. R., Shah, A. M. & Solomon, S. D. Diastolic Dysfunction and Hypertension. Med Clin North Am 101, 7–17, https://doi.org/10.1016/j.mcna.2016.08.013 (2017).
13. Verma, A. & Solomon, S. D. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am 93, 647–664, https://doi.org/10.1016/j.mcna.2009.02.013 (2009).
14. Wan, S. H., Vogel, M. W. & Chen, H. H. Pre-clinical diastolic dysfunction. J Am Coll Cardiol 63, 407–416, https://doi.org/10.1016/j.jacc.2013.10.063 (2014).
15. Redfield, M. M. et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. Jama 289, 194–202, https://doi.org/10.1001/jama.289.2.194 (2003).
16. Verdecchia, P. et al. Prevalence and determinants of left ventricular diastolic filling abnormalities in an unselected hypertensive population. Eur Heart J 11, 679–691, https://doi.org/10.1093/oxfordjournals.eurheartj.a59783 (1990).
17. de Simone, G. et al. Left ventricular concentric geometry is associated with impaired relaxation in hypertension: the HyperGEN study. Eur Heart J 26, 1039–1045, https://doi.org/10.1093/eurheartj/ehu109 (2005).
18. Yancy, C. W. et al. ACCF/AHA guideline for the management of heart failure: a report from the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62, e147–239, https://doi.org/10.1016/j.jacc.2013.05.019 (2013).
19. Reddy, Y. N. & Borlaug, B. A. Heart Failure With Preserved Ejection Fraction. Circ Probl Cardiol 41, 145–188, https://doi.org/10.1016/j.cpcardiol.2015.12.002 (2016).
20. Redfield, M. M. Heart Failure with Preserved Ejection Fraction. N Engl J Med 375, 1868–1877, https://doi.org/10.1056/NEJMc1511175 (2016).
21. Muthuramu, I. et al. Hepatocyte-Specific SR-BI Gene Transfer Corrects Cardiac Dysfunction in Scarb1-Deficient Mice and Improves Pressure Overload-Induced Cardiomyopathy. Arterioscler Thromb Vasc Biol 38, 2028–2040, https://doi.org/10.1161/ATVBAHA.118.310946 (2018).
22. Amin, R. et al. Selective HDL-Raising Human Apo A-1 Gene Therapy Counteracts Cardiac Hypertrophy, Reduces Myocardial Fibrosis, and Improves Cardiac Function in Mice with Chronic Pressure Overload. Int J Mol Sci 18, https://doi.org/10.3390/ijms18092012 (2017).
23. Aboumsallem, J. P. et al. Successful treatment of established heart failure in mice with recombinant HDL (Milano). Br J Pharmacol 175, 4167–4182, https://doi.org/10.1111/bph.14463 (2018).
61. Kempen, H. J. et al. Effect of repeated apoA-1/Milano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys. J Lipid Res 54, 2341–2353, https://doi.org/10.1194/jlr.M033779 (2013).
62. Muthuramu, I. et al. Selective homocysteine-lowering gene transfer attenuates pressure overload-induced cardiomyopathy via reduced oxidative stress. J Mol Med 93, 609–618, https://doi.org/10.1007/s00109-015-1281-3 (2015).
63. Muthuramu, I. et al. Coconut Oil Aggravates Pressure Overload-Induced Cardiomyopathy without Inducing Obesity, Systemic Insulin Resistance, or Cardiac Steatosis. Int J Mol Sci 18, 1565, https://doi.org/10.3390/ijms18071565 (2017).
64. Junqueira, L. C., Bignolas, G. & Brentani, R. Picrosirius staining plus polarization microscopy: a specific method for collagen detection in tissue sections. Histochem J 11, 447–455, https://doi.org/10.1007/BF01002772 (1979).
65. Van Craeyveld, E., Jacobs, F., Gordts, S. C. & De Geest, B. Low-density lipoprotein receptor gene transfer in hypercholesterolemic mice improves cardiac function after myocardial infarction. Gene Ther 19, 860–871, https://doi.org/10.1038/gt.2011.147 (2012).
66. Gordts, S. C. et al. Beneficial effects of selective HDL-raising gene transfer on survival, cardiac remodelling and cardiac function after myocardial infarction in mice. Gene Ther 20, 1053–1061, https://doi.org/10.1038/gt.2013.30 (2013).

Acknowledgements
Ilayaraja Muthuramu is a postdoctoral fellow of the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen. This research was funded by grant GOA3114N of the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen.

Author contributions
M.M., I.M., H.K. and B.D.G. conceived and designed the experiments; M.M., I.M. and B.D.G. analysed the data; M.M. and B.D.G. wrote the paper; M.M., I.M., H.K. and B.D.G. checked the intellectual content of the paper and revised the manuscript; and B.D.G. was responsible for funding acquisition.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-65255-y.

Correspondence and requests for materials should be addressed to B.D.G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020